Accelerator Life Science Partners
Accelerator Life Science Partners is a venture capital firm established in 2003, with headquarters in Seattle, Washington, and additional offices in New York City and San Diego. The firm specializes in the incubation and early-stage investment in life sciences, biotechnology, and therapeutics companies, focusing primarily on seed and start-up ventures. Accelerator Life Science Partners does not engage in subsequent financing rounds, typically investing up to $2 million per company and maintaining investments for 12 to 24 months. The firm provides a wide range of business, scientific, and financial resources to support the development and commercialization of innovative biotechnology discoveries. Its investment activities are primarily concentrated in New York City and Seattle.
KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is to develop the first-in-class immuno- and targeted therapies to drive cures in advanced cancers KayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
Rodeo Therapeutics is a drug development company focused on novel enzyme target and biological pathway that play a critical role in tissue repair and regeneration. Rodeo’s initial goal is to develop novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant.
Magnolia Neurosciences aims to discover and develop proprietary, selective, and drug-like small molecule therapeutics for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions. Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company.
Proniras Corp is an operator of a biomedical company intended to develop drugs. The company's biomedical service has already demonstrated preclinical efficacy in treating nerve agent-induced seizures, as well as in studies of rodents exposed to the chemical weapon soman, which is more toxic than sarin gas, enabling medical researchers to continue their research work and discover drugs. It was founded in 2016 and is headquartered in Seattle, Washington.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.